Clay Siegall, who is an expert in cancer therapies, had a career characterized by several professional accomplishments. Siegall is known in the biotech industry for coming up with Seattle Genetics, a firm that he runs as CEO. The Seattle-based biotech company has developed therapy drugs for diverse diseases.
Siegall’s Education Background
Siegall holds a doctorate in genetics that he acquired from George Washington University and bachelors’ of science in zoology obtained from the University of Maryland. He usually pays attention to the emerging technologies related to cancer therapies. He also believes that traditional cancer treatments, such as chemotherapy should be replaced with new technologies, such as the antibody drug conjugate.
Siegall’s Entrepreneurial Journey in the Biotech Sector
As he was pursuing his undergraduate degree in Zoology, Siegall was passionate about medicine. He was fascinated by the role of technology in treating life-threatening diseases. He started paying close attention to cancer treatment methodologies after his relative, who had cancer, almost died when undergoing chemotherapy.
After school, Clay Siegall worked for Bristol, a leading scientific research company, as a senior researcher. He worked on several biotech innovations patented by the company, which grossed over $80 million in one year. He decided to leave Bristol and come up with Seattle Genetics because of his ambition run his own profitable firm.
Today, Seattle Genetics has established alliances with leading drug manufacturers, such as Pfizer, Bayer, and Genentech. The FDA also approved a drug, which relies on the antibody drug conjugate technology that was developed by the biotech company. Seattle Genetics began as a small startup in the biotech sector. Under Siegall’s CEO tenure, the firm’s professional team encompassed leading researchers and executives in the cancer research field.
Seattle Genetics generates most of its revenue from selling proprietary drugs. An example is Seattle’s flagship product, ADCetris that made history as the first FDA-certified antibody drug conjugate. The firm also makes money from production alliances with companies, such as Genentech and patenting of technologies. It took Seattle Genetics ten years to be profitable. Its professionals also employ effective marketing strategies by taking time to negotiate and organize consultative meetings.